168712_bioimage

Peter J. Prommer



Peter Prommer is a partner in the Intellectual Property group and is a member of our Life Sciences Industry team. He advises small growing companies to leading global corporations on how to develop and protect their intellectual property assets.

What do you focus on?

Leveraging my past experiences in university research and as a licensed professional engineer with an international engineering consulting firm, I understand the creative and problem solving processes in the development of intellectual property. I counsel clients on implementing effective intellectual property strategies that include value-enhancing solutions. In addition to advising U.S.-based companies, I also assist foreign entities on various business issues as they consider furthering their activities into the U.S. market.

Intellectual Property Strategies

I work with clients to devise effective strategies, both foreign and domestic, for building and strengthening their intellectual property portfolios in a manner that aligns with their business objectives. This includes counseling clients on patents, trademarks, IP portfolio development and competitive intelligence, as well as opinion and enforcement matters.

Patents

I execute effective strategies for procuring U.S. and foreign patents in software, mechanical, electromechanical, and materials science technologies. I further work with clients on opinions, as well as post-issuance matters including enforcement, inter partes review, and other post-grant proceedings. My representative experience includes a variety of technologies such as wearable devices, digital healthcare solutions, software-based systems, microfluidic systems, medical devices, optical systems, imaging systems, computer hardware, propulsion systems, battery systems, consumer goods, composite materials, and infrastructure systems.

What do you see on the horizon?

Patent-eligible subject matter continues to be an issue, particularly for software and computer-implemented inventions. This area of law continues to evolve following the Alice Corp. v. CLS Bank ruling by the Supreme Court and the ongoing efforts by the Federal Circuit to interpret the decision. I continue to analyze patent protection strategies that minimize risk in this area to allow companies to more effectively grow their intellectual property.

Presentations

  • “Intellectual Property Strategies to Improve Your Company's Competitiveness,” Chicago Connectory, Webinar, June 16, 2020 (Speaker)
  • “Intellectual Property in SMEs – How IP Strategies Can Improve Your Competitiveness,” German American Chamber of Commerce of the Midwest Business Luncheon, Schaumburg, IL, March 4, 2020 (Speaker)
  • “Wired Attire: The IP and Business of Wearable Tech,” Nixon Peabody’s Modern IP Lawyer: A Boot Camp for Success Seminar, Chicago, IL, June 8, 2017 (Moderator)
  • “Post-Grant Challenges: Recent Decisions and the (Slow) Growth of PGR Proceedings,” Nixon Peabody IP Corporate Seminar, Chicago, June 2, 2016 (Speaker)
  • “Update on Inter Partes and Post-Grant Reviews,” Nixon Peabody IP Corporate Seminar, Chicago, June 2, 2015 (Speaker)
  • “Patent Killers? What the New AIA Post-Grant Challenges Tell Us About the Future of Patents,” Nixon Peabody IP Corporate Seminar, Chicago, June 3, 2014 (Speaker)
  • “Staying Out of Trouble While Being Social: Ethical Dilemmas Posed by Social Media,” Nixon Peabody’s Spring CLE Symposium on Intellectual Property, Chicago, May 2012 (Speaker)
  • “Recent Developments—Trademarks,” Nixon Peabody IP Corporate Seminar, Chicago, June 2011 (Speaker)

Representative Experience

  • Represent leading health care and technology companies on strategically building international patent portfolios related to wearable devices, durable medical devices, digital healthcare solutions, monitoring devices, and health care management systems
  • Represent international leaders in engineering, manufacturing, and scientific research software technologies on strategically building and protecting intellectual property portfolios
  • Represent world-renowned research institutions on licensed and non-licensed technologies directed to microfluidic cell culture devices, medical imaging, positioning systems, and microelectromechanical system (MEMS) technologies
  • Represent leading computer hardware manufacturers on strategically building and protecting intellectual property portfolios, including in inter partes review (IPR) proceedings before the Patent Trial and Appeal Board (PTAB)
  • Represent both plaintiffs and defendants on patent litigation and other intellectual property matters for medical device, imaging, and digital technologies
  • Counsel foreign companies on U.S. market entry activities

More Certainty on Limits to Early Section 101 Challenges – How Will This Impact Patent Owners and Applications?

Intellectual Property & Technology Law Journal | May 01, 2020

Intellectual Property partner Pete Prommer in Chicago and associate Ravi Braich, Ph.D. in Boston contributed this article analyzing the Supreme Court’s denial of several petitions for certiorari on patent decision in HP Inc. v. Berkheimer, and the effect on patent owners and applicants. Click here for the full article.

Contact

Peter J. Prommer

Partner

Chicago

Phone: 312-425-8552


Fax: 866-495-2308

University of Illinois, J.D., magna cum laude

Bucerius Law School, International and Comparative Business Law Program, Hamburg, Germany

Northwestern University, M.S., Walter P. Murphy Fellow

University of Illinois at Urbana-Champaign, B.S., with honors

Illinois

U.S. District Court, Northern District of Illinois

U.S. Court of Appeals, Federal Circuit

U.S. Patent and Trademark Office

German

The Illinois Super Lawyers publication has recognized Peter as a top rated attorney in intellectual property law.

Peter currently serves on the Board of Managers and as an officer of the Intellectual Property Law Association of Chicago (IPLAC). In addition, he currently serves on the Transatlantic Advisory Council of Bucerius Law School, a private law school in Hamburg, Germany, founded two decades ago by ZEIT-Stiftung.

Back to top